0000899243-20-030759.txt : 20201110
0000899243-20-030759.hdr.sgml : 20201110
20201110211708
ACCESSION NUMBER: 0000899243-20-030759
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201109
FILED AS OF DATE: 20201110
DATE AS OF CHANGE: 20201110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Snodgres Jon
CENTRAL INDEX KEY: 0001613498
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-14656
FILM NUMBER: 201302780
MAIL ADDRESS:
STREET 1: REPLIGEN CORPORATION, 41 SEYON STREET
STREET 2: BUILDING #1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02435
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REPLIGEN CORP
CENTRAL INDEX KEY: 0000730272
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 042729386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 7814499560
MAIL ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-09
0
0000730272
REPLIGEN CORP
RGEN
0001613498
Snodgres Jon
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
WALTHAM
MA
02453
0
1
0
0
Chief Financial Officer
Common Stock
2020-11-09
4
S
0
705
194.69
D
31562
D
Common Stock
2020-11-09
4
M
0
1893
59.52
A
33455
D
Common Stock
2020-11-10
4
M
0
3086
32.40
A
36541
D
Common Stock
2020-11-10
4
S
0
3086
193.00
D
33455
D
Stock Option (Right to Buy)
59.52
2020-11-09
4
M
0
1893
0.00
D
2029-02-28
Common Stock
1893
3788
D
Stock Option (Right to Buy)
32.40
2020-11-10
4
M
0
3086
0.00
D
2027-02-23
Common Stock
3086
0
D
$194.69 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.56 to $194.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares vest and become exercisable as follows: 1,894 shares on 2/28/2021 and 1,894 shares on 2/28/2022.
This option is currently exercisable.
/s/ Jeffrey P. Leduc (Attorney in Fact)
2020-11-10